David S. Hewings
Vertex Pharmaceuticals (United Kingdom)(GB)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Computational Drug Discovery Methods, Melanoma and MAPK Pathways, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography
Most-Cited Works
- → 3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands(2011)222 cited
- → Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions(2012)185 cited
- → Small Molecule Inhibitors of Bromodomain–Acetyl-lysine Interactions(2014)172 cited
- → Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands(2013)138 cited
- → Activity‐based probes for the ubiquitin conjugation–deconjugation machinery: new chemistries, new tools, and new insights(2017)117 cited
- → Reactive-site-centric chemoproteomics identifies a distinct class of deubiquitinase enzymes(2018)86 cited
- → The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains(2012)66 cited
- → Organocatalytic removal of formaldehyde adducts from RNA and DNA bases(2015)51 cited
- → Activity‐based probes for the multicatalytic proteasome(2017)38 cited
- → Discovery of Novel Allosteric EGFR L858R Inhibitors for the Treatment of Non-Small-Cell Lung Cancer as a Single Agent or in Combination with Osimertinib(2022)35 cited